The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- Dry January: Exploring the Health Benefits of Reducing Alcohol Intake
- Top Winter Wellness Tips for Healthcare Providers and Patients
- The Rise of Plant-Based Diets: What Healthcare Providers Should Know
- The Importance of Continuing Medical Education for Healthcare Providers
- Beyond the Hospital Walls: The Adventure of Travel Nursing